Clinical trial
Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia
NCT00270478 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00270478 |
|---|---|
| Title | Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia |
| Official title | Evaluation of Synergy of Combining Hydroxyurea With Recombinant Human Erythropoietin Glycoform Alpha (Rhu Erythropoietin-alpha) on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Sickle Cell Disease, Chronic Kidney Disease, Pulmonary Hypertension |
| Intervention type | Drug |
| Interventions | Erythropoietin and Hydroxyurea |
| Enrollment | 7 |
| Start date | Dec 21, 2005 |
| Primary completion | Aug 31, 2009 |
| Completion | Aug 31, 2009 |
| First posted | Dec 26, 2005 |
| Last update posted | Dec 17, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: